drugset
drugset / Trial / NCT00025584

PS-341 in Treating Women With Metastatic Breast Cancer

NCT00025584 ↗

Phase 2 Completed 35 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer

Timeline

Start
2001-08
Primary completion
2004-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — Intravenous

Indications

female breast carcinoma